Tumor-associated carbohydrate antigens: a possible avenue for cancer prevention

Area of Science:

• Immunology
• Oncology
• Vaccinology

Background:

• Tumor-associated carbohydrate antigens (TACA) are highly expressed in carcinomas.
• CD8+ T cells (CTL) can recognize TACA in a class I MHC-restricted manner.
• Glycopeptides are emerging as potential vaccine candidates for cancer prevention.

Purpose of the Study:

• To investigate the efficacy of glycopeptides containing TACA as preventive vaccines for carcinomas.
• To assess the immunogenicity of designer glycopeptides targeting TACA.
• To explore the potential of glycopeptide vaccines for broad population use.

Main Methods:

• Conjugation of TACA (Thomsen-Friedenreich antigen and Tn) to designer peptides with high affinity for class I MHC molecules.
• Generation of TACA-specific CTL using glycopeptide vaccines.
• In vitro assessment of CTL recognition of TACA-expressing tumor cells.
• Testing immunogenicity in mice with TACA-expressing mammary tumors.
• Evaluating designer glycopeptides for binding to multiple HLA alleles.

Main Results:

• Glycopeptides conjugated to designer peptides function as Th-independent vaccines.
• Generated TACA-specific CTL recognize TACA-expressing tumors in vitro.
• Glycopeptides are presented by class I MHC molecules similarly to non-glycosylated peptides.
• Mice with TACA-expressing tumors are not tolerant to glycopeptide vaccination.
• Designer glycopeptides show immunogenicity and high CTL response efficiency in vitro.

Conclusions:

• Glycopeptide-based vaccines elicit effective anti-tumor CTL responses.
• Designer glycopeptides can be developed to target a broad population.
• This approach offers a novel strategy for designing prospective cancer prevention vaccines.